Partnering with general practitioners to optimize survivorship for patients with lymphoma: a phase II randomized controlled trial (the GOSPEL I trial)

BACKGROUND: Survival rates for lymphoma are highest amongst hematological malignancies. In 2019, it was estimated that over 6400 Australians were diagnosed with lymphoma, a group of hematological malignancies with a high 5-year survival rate of ~ 76%. There is an increased focus on the promotion of...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Raymond Javan, Buhagiar, Stephanie, Teleni, Laisa, Simonsen, Camilla, Turner, Jane, Rawson, Courtney, Hart, Nicolas H., Jones, Lee, Gordon, Louisa, Joseph, Ria, Agbejule, Oluwaseyifunmi Andi, Henderson, Fiona, Rhee, Joel, Ryan, Marissa, Carrington, Christine, Mapp, Sally
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787240/
https://www.ncbi.nlm.nih.gov/pubmed/33407797
http://dx.doi.org/10.1186/s13063-020-04945-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787240/
https://www.ncbi.nlm.nih.gov/pubmed/33407797
http://dx.doi.org/10.1186/s13063-020-04945-4

Ejemplares similares